SEVO Bioscience

Creating the world’s first oral vaccines for farmed fish

Bringing vaccines at-sea.

Dilan Jaunky, PhD – CEO and Founder | 2026



Photo: Sernapesca [1]

Diseases Destroy Biomass at Sea

Fresh Water

Sea Water









Smolt
0.08 – 0.3 kg

Year 0-1
0.3 - 2kg

Year 1-2
2-4kg

Harvest
4-5kg

Vaccination (Injectable)


Salmon are exposed to diseases

No Booster Available!

SEVO Bioscience

THE SOLUTION

KYVAX™ — Oral Vaccines for Farmed Fish



SEVO Bioscience

MARKET OPPORTUNITY

KYVAX™ Owning a 15.2B Dose Market

TAM $4.6B - 15.2B Doses

Six viral diseases affecting salmon globally

SAM $744M – 2.4B Doses

ISA Vaccines for Norway, Chile & Scotland


SOM $18.6M – 62M Doses

ISA Vaccines for Canada



SEVO Bioscience

Key Players in Fish Therapeutics



SEVO Bioscience


BUSINESS MODEL

Licensing KYVAX™ for One Viral Disease

62M Doses



1,582M Doses



2.4B Doses

=

$744M

688M Doses



148M Doses



8% royalty

$60M

per year

Single disease - single species

Licenses stack per disease x species x geographies


Potential licensee

- Feed manufacturers
- Aquaculture Farmers
- CDMOs
- Animal health Companies

Assuming 100% market penetration for 1 disease

SEVO Bioscience

Funding Path to Commercial Sales



SEVO Bioscience

GO-TO-MARKET TRACTION

Validation Across the Aquaculture Value Chain

● Signed ○ In discussion

Discovery & Design	Preclinical Efficacy	Scale-Up & Production	Regulatory	Route to Market
NRC ● Formulation and *in vitro* testing	**UPEI, Dr. Mark Fast** ○ ISA challenge and efficacy trials	**NRC** ● Bioprocess scale-up pre-commercial scale	**Onda** ○ Certified ISA challenge and efficacy trials	**Feed Manufacturer** ● Global aquafeed leader, under NDA
CRBM ● Genomics and analysis	**Dalhousie** ● Independent validation	**CDMO** ○ Biomass manufacturing at commercial scale	**Regulatory advisory** ○ CFIA and Veterinary Biologics approval pathway	**Mayank Aqua Products** ● India

SEVO Bioscience

THE ASK

What We Are Raising and Why

CAD $600K

Pre-seed convertible note (SAFE available)



CAD $200K received CAD $400K open

Non-Dilutive Secured Outside the Pre-Seed

CAD $580K non-dilutive

16 to 24 Month Milestones
Hire senior R&D talent
Conduct ISA disease challenge pilot studies with partner
Sign commercial agreement with aquaculture farmer
Prepare pre-submission dossier to CFIA/CCVB

BEYOND CAPITAL

- Intros to HNW individuals in ocean health and food security
- Philanthropic and foundation funding
- Warm intros to fish health operators

SEVO Bioscience

THE TEAM

Who Are We



Dilan B. Jaunky,
PhD
CEO and Founder



Steven Slater,
PhD
COO



Brandon Jaunky, MSc
Business Relations



Chensong Liu, MBA
Financial Analyst

Key Advisors

Jason Cleaversmith, PhD, MBA - Emergence

Margaret Bywater, MD – Ex-CEO Morphocell

Key Consultants

Laurent Genet, DVM – Ex-CSO at Nutreco

Pawan Agrawal, PhD – Ex-CFIA/CCVB at HC

SEVO Bioscience

Recode life.
Redefine possible.

Let's talk — info@sevobioscience.com · sevobioscience.com